Wockhardt initiates global Phase III clinical study of WCK 5222

16 Aug 2022 Evaluate

Wockhardt has initiated global Phase III clinical study of its new antibiotic candidate WCK 5222. The company has completed the first site initiation visit for the study. This is double-blind, multi-center, efficacy, safety, and tolerability study in the treatment of hospitalized adults with Complicated Urinary Tract Infections, including Acute Pyelonephritis. This Study will have 70 centres worldwide in 11 countries including US, Europe, India, China and Latin America. This global study is expected to be completed in 18 months.

Wockhardt is a research based global pharmaceutical and Biotech Company headquartered in Mumbai, India.

Wockhardt Share Price

1448.95 -12.20 (-0.83%)
27-Dec-2024 10:22 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.75
Dr. Reddys Lab 1374.10
Cipla 1503.00
Lupin 2208.10
Zydus Lifesciences 969.20
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.